Aimmune Therapeutics, Inc. (AIMT) Insider Douglas T. Sheehy Sells 3,750 Shares

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Douglas T. Sheehy sold 3,750 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $37.00, for a total transaction of $138,750.00. Following the transaction, the insider now directly owns 3,750 shares in the company, valued at $138,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at $36.20 on Tuesday. Aimmune Therapeutics, Inc. has a twelve month low of $15.97 and a twelve month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.09. equities analysts expect that Aimmune Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of AIMT. Citadel Advisors LLC raised its holdings in Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after acquiring an additional 542,111 shares in the last quarter. Vanguard Group Inc. raised its holdings in Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after acquiring an additional 513,803 shares in the last quarter. State Street Corp raised its holdings in Aimmune Therapeutics by 49.1% in the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after acquiring an additional 282,744 shares in the last quarter. Eagle Asset Management Inc. increased its stake in Aimmune Therapeutics by 6.3% during the second quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after purchasing an additional 135,374 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Aimmune Therapeutics by 139.9% during the second quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after purchasing an additional 132,603 shares during the last quarter. 73.34% of the stock is currently owned by hedge funds and other institutional investors.

AIMT has been the topic of a number of recent research reports. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Wedbush reissued an “ourperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a research report on Saturday, October 21st. Finally, Credit Suisse Group upped their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Hold” and an average target price of $49.40.

ILLEGAL ACTIVITY WARNING: “Aimmune Therapeutics, Inc. (AIMT) Insider Douglas T. Sheehy Sells 3,750 Shares” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/05/aimmune-therapeutics-inc-aimt-insider-douglas-t-sheehy-sells-3750-shares.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

What are top analysts saying about Aimmune Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit